Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
May 21 2024 - 8:00AM
Protara Therapeutics, Inc.
(Nasdaq: TARA), a
clinical-stage company developing transformative therapies for the
treatment of cancer and rare diseases, today announced that
management will participate in a virtual fireside chat at the TD
Cowen 5th Annual Oncology Innovation Summit on Tuesday, May 28,
2024 at 3:00 pm ET.
A live webcast of the fireside chat can be accessed by visiting
the Events and Presentations section of the Company’s
website: https://ir.protaratx.com. The webcast will be
archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to
advancing transformative therapies for people with cancer and rare
diseases. Protara’s portfolio includes its lead candidate,
TARA-002, an investigational cell-based therapy in development for
the treatment of non-muscle invasive bladder cancer (NMIBC) and
lymphatic malformations (LMs). The Company is evaluating TARA-002
in an ongoing Phase 2 trial in NMIBC patients with carcinoma in
situ (CIS) who are unresponsive or naïve to treatment with Bacillus
Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric
patients with LMs. Additionally, Protara is developing IV Choline
Chloride, an investigational phospholipid substrate replacement for
patients on parenteral nutrition who are otherwise unable to meet
their choline needs via oral or enteral routes. For more
information, visit www.protaratx.com.
Company Contact:Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Sep 2023 to Sep 2024